WO2012015200A3 - 간 질환의 진단, 치료 및 예방용 조성물 - Google Patents

간 질환의 진단, 치료 및 예방용 조성물 Download PDF

Info

Publication number
WO2012015200A3
WO2012015200A3 PCT/KR2011/005444 KR2011005444W WO2012015200A3 WO 2012015200 A3 WO2012015200 A3 WO 2012015200A3 KR 2011005444 W KR2011005444 W KR 2011005444W WO 2012015200 A3 WO2012015200 A3 WO 2012015200A3
Authority
WO
WIPO (PCT)
Prior art keywords
liver disease
tm4sf5
expression
composition
grade
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/005444
Other languages
English (en)
French (fr)
Other versions
WO2012015200A2 (ko
Inventor
이정원
박기훈
강민경
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Original Assignee
SNU R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020100125743A external-priority patent/KR20120022504A/ko
Application filed by SNU R&DB Foundation filed Critical SNU R&DB Foundation
Priority to US13/813,135 priority Critical patent/US9057725B2/en
Publication of WO2012015200A2 publication Critical patent/WO2012015200A2/ko
Publication of WO2012015200A3 publication Critical patent/WO2012015200A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 간 질환의 진단, 치료 및 예방용 조성물에 관한 것으로, 더욱 상세하게는, TM4SF5(Transmembrane 4 L six family member 5 또는 Four-Transmembrane L6 Superfamily member 5) 단백질 수준을 측정하는 물질을 포함하는 간 질환 진단용 조성물, 상기 조성물을 포함하는 간 질환 진단용 키트, TM4SF5 단백질 수준 및 TM4SF5 발현 관련 신호전달 단백질들의 발현 및 인산화 수준을 측정하여, 정상 대조군 시료와 비교하는 간 질환의 진단을 위한 정보 제공 방법, 간 질환 치료 물질의 스크리닝 방법, 및 TM4SF5 단백질의 발현 또는 TM4SF5 발현 관련 신호전달 단백질들의 발현 및 인산화를 저해하는 물질을 포함하는 간 질환 치료 또는 예방용 조성물에 관한 것이다. 본 발명은 간 질환에 있어서, TM4SF5 발현 수준 측정 및 TM4SF5 발현 관련 신호전달 단백질들의 발현 및 인산화 수준을 측정을 통해, 간질환의 진단 및 치료 물질의 스크리닝 등이 가능하며, 상기 TM4SF5에 대한 길항제를 이용하여 간 질환의 예방 및/또는 치료 또한 가능하다.
PCT/KR2011/005444 2010-07-30 2011-07-22 간 질환의 진단, 치료 및 예방용 조성물 Ceased WO2012015200A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/813,135 US9057725B2 (en) 2010-07-30 2011-07-22 Composition for diagnosing, treating, and preventing liver disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR10-2010-0074256 2010-07-30
KR20100074256 2010-07-30
KR10-2010-0125743 2010-12-09
KR1020100125743A KR20120022504A (ko) 2010-07-30 2010-12-09 간 질환의 진단, 치료 및 예방용 조성물
KR1020110072902A KR101368871B1 (ko) 2010-07-30 2011-07-22 간 질환의 진단, 치료 및 예방용 조성물
KR10-2011-0072902 2011-07-22

Publications (2)

Publication Number Publication Date
WO2012015200A2 WO2012015200A2 (ko) 2012-02-02
WO2012015200A3 true WO2012015200A3 (ko) 2012-09-27

Family

ID=45530578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/005444 Ceased WO2012015200A2 (ko) 2010-07-30 2011-07-22 간 질환의 진단, 치료 및 예방용 조성물

Country Status (1)

Country Link
WO (1) WO2012015200A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9631012B2 (en) * 2013-02-26 2017-04-25 Industry Academic Cooperation Foundation, Hallym University Antibodies against TM4SF5 and methods of use thereof
WO2019124608A1 (ko) * 2017-12-22 2019-06-27 경상대학교병원 4'-(p-톨루엔설포닐아미도)-4-하이드록시칼콘을 유효성분으로 함유하는 류마티스 관절염 예방 또는 치료용 약학 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070097934A (ko) * 2006-03-30 2007-10-05 재단법인 한국원자력의학원 간암 환자 생존기간 예측용 마커, 그를 포함하는 키트 및마이크로어레이, 및 상기 마커를 이용한 간암 환자생존기간 예측 방법
KR100934706B1 (ko) * 2006-12-07 2009-12-31 재단법인서울대학교산학협력재단 Ｔｍ４ｓｆ５의 기능을 저해하는 항암물질의 스크리닝 방법및 칼콘계 화합물을 함유하는 항암조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070097934A (ko) * 2006-03-30 2007-10-05 재단법인 한국원자력의학원 간암 환자 생존기간 예측용 마커, 그를 포함하는 키트 및마이크로어레이, 및 상기 마커를 이용한 간암 환자생존기간 예측 방법
KR100934706B1 (ko) * 2006-12-07 2009-12-31 재단법인서울대학교산학협력재단 Ｔｍ４ｓｆ５의 기능을 저해하는 항암물질의 스크리닝 방법및 칼콘계 화합물을 함유하는 항암조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
F. MULLER-PILLASCH ET AL.: "Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer.", GENE, vol. 208, no. 1, 1998, pages 25 - 30, XP004132007, DOI: doi:10.1016/S0378-1119(97)00633-1 *
SIN-AE LEE ET AL.: "Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma.", THE JOURNAL OF CLINICAL INVESTIGATION., vol. 118, no. 4, 2008, pages 1354 - 1366, XP002579276, DOI: doi:10.1172/JCI33768 *

Also Published As

Publication number Publication date
WO2012015200A2 (ko) 2012-02-02

Similar Documents

Publication Publication Date Title
US20170023591A1 (en) Traumatic Brain Injury and Neurodegenerative Biomarkers, Methods, and Systems
WO2009077864A3 (en) Compositions and methods of detecting tiabs
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
WO2014036495A3 (en) Diagnostic assays and kits for detection of folate receptor 1
Haris et al. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease
Nadri et al. GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients
WO2011133770A3 (en) Salivary protein markers for detection of breast cancer
Metanat et al. Acute Q fever among febrile patients in Zahedan, southeastern Iran
CN109521204A (zh) 一种狼疮抗凝物检测试剂及其制备方法和使用方法
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
Le Corre et al. Quantification of the calcification phenotype of Abcc6-deficient mice with microcomputed tomography
Blackbeard et al. Quantification of the rat spinal microglial response to peripheral nerve injury as revealed by immunohistochemical image analysis and flow cytometry
WO2012015200A3 (ko) 간 질환의 진단, 치료 및 예방용 조성물
WO2008067806A3 (de) Diagnose und risikostratifizierung von herzinsuffizienz mittels neurophysin
D’mello et al. Selected GRIN2A mutations in melanoma cause oncogenic effects that can be modulated by extracellular glutamate
RU2008103988A (ru) Способ диагностики рассеяного склероза
Fu et al. The α2δ-1-NMDAR1 interaction in the trigeminal ganglion contributes to orofacial ectopic pain following inferior alveolar nerve injury
Ohnuma et al. Expression of Fyn, a non-receptor tyrosine kinase in prefrontal cortex from patients with schizophrenia and its correlation with clinical onset
Nemoto et al. Inhibitory effect of angiotensin (1-7) on angiotensin III-induced nociceptive behaviour in mice
JP2021099351A (ja) 生体サンプル中のミトコンドリア複製の機能不全をインビトロで調査するための方法、そのキット及び使用、早老症様の症候群又は症状に対する治療方法、並びに特定のプロテアーゼ阻害剤及び／又はニトロソ酸化還元ストレススカベンジャー化合物を同定するためのスクリーニング方法
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
WO2002033420A3 (en) A urine test for the diagnosis of prion diseases
ATE557277T1 (de) Verfahren zur diagnose von endometriose mittels tfpi-2 protein
DE102008022609B4 (de) Verfahren zum Nachweis des Vorkommens von Nierensteinen und/oder Entzündungen der ableitenden Harnwege
WO2005040806A3 (en) Use of protein asc as a marker for breast cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11812730

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13813135

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 11812730

Country of ref document: EP

Kind code of ref document: A2